NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Drug Manufacturers - Specialty & Generic · USD

Hims & Hers Health, Inc. (HIMS) Stock Analysis

Hims & Hers Health, Inc. (HIMS) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE and quoted in US Dollar.

HIMS

$27.71

−$0.11 (−0.40%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HIMS with… →

HIMS Key Statistics

As of Sep 4, 2026
Trading
Open
$27.73
Previous Close
$27.82
Day's Range
27.38–27.95
52-Week Range
13.74–65.30
Volume
7.14M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.41
Valuation
Market Cap
$6.47B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
36.35
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.54
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.51
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.64
Financials (FY)
Revenue (FY)
$2.35B+59.00%
Net Income (FY)
$128.37M+1.85%
Profit marginThe share of revenue left as profit after all costs and taxes.
−5.51%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
224.94M
1-Year Return
−42.40%
Dividend and dates
Earnings Date
November 9, 2026
Avg Volume
15.10M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

HIMS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−14.66%
2025+34.28%
2024+171.69%
2023+38.85%
2022−2.14%
2021−55.14%
2020+47.47%
2019 (partial year)+1.02%

As of September 4, 2026.

HIMS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.35B$128.37M5.5%
2024$1.48B$126.04M8.5%
2023$872.00M−$23.55M−2.7%
2022$526.92M−$65.68M−12.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.35B$1.73B$105.61M$128.37M5.5%
2024$1.48B$1.17B$61.90M$126.04M8.5%
2023$872.00M$714.95M−$29.45M−$23.55M−2.7%
2022$526.92M$408.72M−$68.70M−$65.68M−12.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

HIMS Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricHIMSDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio2.512.309% above
Profit margin−5.51%−3.14%2.4 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Hims & Hers Health, Inc. (HIMS) at $6.47B. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 2,442 employees.

The 52-week range on file runs from $13.74 to $65.30. The most recent close on file for HIMS is $27.71, dated September 4, 2026. That is −$0.11 (−0.40%) against the previous close. The latest close sits 101.67% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $2.35B. That is +59.00% against the prior fiscal year, when revenue was $1.48B. The same year closed with net income of $128.37M. That is +1.85% against the prior fiscal year. Profit margin runs at −5.51%. That is 2.4 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −0.64.

Across the 4 fiscal years on file, revenue moves from $526.92M in 2022 to $2.35B in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 36.35. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.54. Measured against sales, the shares trade at 2.51 times revenue. On price-to-sales that is 9.21% above the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −42.40%. Measured over 5 years, that is +27.54% a year compounded. The reported beta is 2.41. Daily returns over the trailing 7 years annualize to a volatility of 77.78%.

Growth & Income

No dividend is on file for HIMS.

Across the complete calendar years on file, 2024 returned +171.69% and 2021 returned −55.14%. Of the 6 complete calendar years on file, 4 finished higher. 2026 is still running; the price is −14.66% year to date.

Peer Comparison

Hims & Hers Health, Inc. (HIMS) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Hims & Hers Health, Inc. HIMS $6.47B —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Hims & Hers Health, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Hims & Hers Health, Inc.

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.

Visit website →